Contacts

Extension of the subscription period

September 25, 2018

MedinCell announces the extension of the subscription period for the shares offered as part of its initial public offering


Jacou, France, September 25, 2018, 10.00 pm CEST – MedinCell, a technological pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, today announces the extension of the subscription period for the shares offered as part of its initial public offering on Euronext Paris.
Initially scheduled on 27 September 2018 until 12 p.m (Paris time), the offer period for the global placement is extended until 3 October at 12 p.m (Paris time). The period of the Open Price Offer is also extended until 2 October at 5 p.m. (Paris time) for subscriptions at the counters and at 8 p.m. (Paris time) for subscriptions via the Internet.
The other characteristics of the operation remain unchanged. In particular, orders issued as part of the Open Price Offer will be maintained unless they have been expressly revoked before the new closing date of the open price offer (included).

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.